Psoriasis Completed Phase 2 Trials for Talarozole (DB13083)

Also known as: Psoriasis unspecified / Psoriasis, unspecified

IndicationStatusPhase
DBCOND0013339 (Psoriasis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00716144Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque PsoriasisTreatment
NCT00725348An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type PsoriasisTreatment